Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07204340
PHASE1

TLN-372 in Advanced KRAS Mutant Solid Tumors

Sponsor: Treeline Biosciences, Inc.

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Official title: An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-09-29

Completion Date

2032-04-01

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

TLN-372

Specified dose on specified days

DRUG

TLN-372 in combination with cetuximab

Specified dose on specified days

DRUG

TLN-372 in combination with pembrolizumab

Specified dose on specified days

Locations (10)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

START Midwest

Grand Rapids, Michigan, United States

Washington University Medical Campus

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Linear Clinical Research

Perth, Western Australia, Australia

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

START Madrid_Hospital Universitario HM Sanchinarro_CIOCC

Madrid, Spain